2024

1. A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy survey

   European Journal of Surgical Oncology, Vol. 50, Núm. 10

2. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

   Nature Communications, Vol. 15, Núm. 1

3. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

   The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

4. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

   Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58

5. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

   Gynecologic Oncology, Vol. 187, pp. 128-138

6. Factors Associated with and Impact of Open Conversion in Laparoscopic and Robotic Minor Liver Resections: An International Multicenter Study of 10,541 Patients

   Annals of surgical oncology, Vol. 31, Núm. 9, pp. 5615-5630

7. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

   Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

8. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

   The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227

9. Himalaya Overall Survival Prominence and Other Routes to the Peak

   JAMA Oncology

10. Impact of Liver Cirrhosis, Severity of Cirrhosis, and Portal Hypertension on the Difficulty and Outcomes of Laparoscopic and Robotic Major Liver Resections for Primary Liver Malignancies

    Annals of Surgical Oncology, Vol. 31, Núm. 1, pp. 97-114

11. Impact of liver cirrhosis, severity of cirrhosis and portal hypertension on the difficulty of laparoscopic and robotic minor liver resections for primary liver malignancies in the anterolateral segments

    European Journal of Surgical Oncology, Vol. 50, Núm. 1

12. Impact of neoadjuvant chemotherapy on short-term outcomes after simple and complex minimally invasive minor hepatectomy for colorectal liver metastases: A propensity-score matched and coarsened exact matched study

    European Journal of Surgical Oncology, Vol. 50, Núm. 6

13. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

14. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

    HemaSphere

15. Management challenges in low-grade serous ovarian cancer with a BRCA mutation

    International Journal of Gynecological Cancer, Vol. 34, Núm. 4, pp. 631-636

16. Patient-Reported Outcomes from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

    Journal of Clinical Oncology, Vol. 42, Núm. 23, pp. 2790-2799

17. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

    Frontiers in Oncology, Vol. 14

18. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

19. Propensity Score-Matching Analysis Comparing Robotic Versus Laparoscopic Limited Liver Resections of the Posterosuperior Segments: An International Multicenter Study

    Annals of surgery, Vol. 279, Núm. 2, pp. 297-305

20. Propensity score-matched analysis comparing robotic versus laparoscopic minor liver resections of the anterolateral segments: an international multi-center study of 10,517 cases

    Annals of Surgery